Foseal 800 Tablet contains Sevelamer 800mg, a non-absorbed phosphate binder used primarily to control hyperphosphatemia in patients with chronic kidney disease (CKD) undergoing dialysis. By binding phosphate in the gastrointestinal tract, Sevelamer helps reduce serum phosphate levels, preventing complications such as secondary hyperparathyroidism, vascular calcification, and bone disorders associated with elevated phosphate. Unlike calcium-based phosphate binders, Foseal 800 does not increase calcium levels, minimizing the risk of hypercalcemia and related cardiovascular issues. It is typically administered orally with meals to maximize phosphate binding from dietary intake. Patients should adhere to prescribed dosages and dietary recommendations to optimize treatment efficacy. Common side effects may include gastrointestinal discomfort, nausea, constipation, or diarrhea, which are generally mild and transient. Foseal 800 is contraindicated in patients with bowel obstruction or hypersensitivity to Sevelamer. Regular monitoring of serum phosphate, calcium, and bicarbonate levels is recommended during therapy. This medication should be used under medical supervision, especially in patients with comorbid conditions. Foseal 800 Tablet offers an effective and safer alternative for managing phosphate levels in CKD patients, improving their overall clinical outcomes and quality of life.